5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole
• 英文别名: 5-fluoro-3-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-1-naphthalen-1-ylsulfonylindole
• 化学式: C₂₄H₂₁FN₂O₂S
• 分子量: 420.507
• InChiKey: CGSFFLVTUXMRJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  50.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-氟-3-(1-甲基-1,2,3,6-四氢-4-吡啶基)-1H-吲哚 、 1-萘磺酰氯 生成 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole
  参考文献：
  名称：

  Piperidine-indole compounds having 5-HT.sub.6 affinity

  摘要：

  本文描述了对5-HT.sub.6受体具有亲和力的化合物，其具有以下通式：其中：R.sup.1选自H和C.sub.1-4烷基的群组；R.sup.2选自H、C.sub.1-4烷基和苄基的群组；——表示单键或双键；R.sup.3选自COR.sup.5和SO.sub.2R.sup.5的群组；R.sup.4a选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基的群组；R.sup.4b选自H、羟基、卤素、C.sub.3-7环烷氧基、C.sub.1-4烷氧基、C.sub.1-4烷基、苄氧基、苯氧基、三氟甲基、三氟甲氧基和乙烯基的群组；R.sup.4c选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基的群组；R.sub.4d选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基的群组；R.sup.5选自苯基、吡啶基、噻吩基、喹啉基和萘基，其中可以选用1-4个从C.sub.1-4烷氧基、C.sub.1-4烷基、卤素、硝基、三氟甲基、三氟甲氧基、1,2-亚甲二氧基、C.sub.1-4烷基羰基、C.sub.1-4烷氧基羰基和C.sub.1-4烷基S--中选择的取代基。还描述了这些化合物作为药物治疗5-HT.sub.6受体受到抑制的疾病，如精神分裂症的用途。

  公开号：

  US06133287A1

文献信息

• PIPERIDINE-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY
  申请人：NPS Allelix Corp.

  公开号：EP1173432B9

  公开（公告）日：2008-10-15
• COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY
  申请人：Codony-Soler Xavier

  公开号：US20100120747A1

  公开（公告）日：2010-05-13

  The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least one cholinesterase inhibitor, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.
• US6133287A
  申请人：——

  公开号：US6133287A

  公开（公告）日：2000-10-17
• [EN] PIPERIDINE-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY<br/>[FR] COMPOSES PIPERIDINE-INDOL AYANT UNE AFFINITE AVEC 5-HT6
  申请人：ALLELIX BIOPHARMA

  公开号：WO2000063203A1

  公开（公告）日：2000-10-26

  Described herein are indole compounds with affinity for the 5-HT6 receptor, which have general formula (I) wherein, R1 is selected from the group consisting of H and C¿1-4?alkyl; R?2¿ is selected from the group consisting of H, C¿1-4?alkyl and benzyl; ----- represents a single or double bond; R?3¿ is selected from the group consisting of COR5 and SO¿2?R?5; R4a¿ is selected from the group consisting of H, OH, halo, C¿1-4?alkyl and C1-4alkoxy; R?4b¿ is selected from the group consisting of H, hydroxy, halo, C¿3-7?cycloalkyloxy, C1-4alkoxy, C1-4alkyl, benzyloxy, phenoxy, trifluoromethyl, trifluoromethoxy and vinyl; R?4c¿ is selected from the group consisting of H, OH, halo, C¿1-4?alkyl and C1-4alkoxy; R?4d¿ is selected from the group consisting of H, OH, halo, C¿1-4?alkyl and C1-4alkoxy; and R?5¿ is selected from the group consisting of phenyl, pyridyl, thienyl, quinolinyl and naphthyl which are optionally substituted with 1-4 substituents selected from C¿1-4?alkoxy, C1-4alkyl, halo, nitro, trifluoromethyl, trifluoromethoxy, 1,2-methylenedioxy, C1-4alkylcarbonyl, C1-4alkoxycarbonyl and C1-4alkylS-. Also described is the use of the compounds as pharmaceuticals to treat indications where inhibition of the 5-HT6 receptor is implicated, such as schizophrenia.
• [EN] COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY<br/>[FR] COMBINAISON D'UN INHIBITEUR DE LA CHOLINESTÉRASE ET D'UN COMPOSÉ AYANT UNE AFFINITÉ ENVERS LE RÉCEPTEUR 5-HT6
  申请人：ESTEVE LABOR DR

  公开号：WO2007147883A1

  公开（公告）日：2007-12-27

  [EN] The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least one cholinesterase inhibitor, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.
  [FR] La présente invention concerne une combinaison de substances actives comprenant au moins un composé ayant une affinité pour le récepteur 5-HT6 et au moins un inhibiteur de la cholinestérase. L'invention concerne également un médicament comprenant ladite combinaison de substances actives et l'utilisation de ladite combinaison lors de la fabrication d'un médicament.